China Pharma Holdings Inc.

Company Overview

Business Model: China Pharma Holdings, Inc. is a Nevada holding company that operates through its wholly owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), and Helpson's subsidiaries in the People's Republic of China (PRC). The Company is primarily engaged in the development, manufacture, and marketing of pharmaceutical products for human use, targeting high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. Helpson manufactures dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of products are prescription-based and approved by the National Medical Products Administration (NMPA). The Company also manufactures comprehensive healthcare products and protective products.

Market Position: The Company operates in a highly policy-driven and fragmented pharmaceutical industry in China, characterized by a large number of small and medium-sized manufacturers and fierce competition. It focuses on generic drugs with large addressable markets and higher profit margins, as well as Modern Traditional Chinese Medicines. The Company leverages an academic-driven promotion model to directly supply products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistic companies. It is actively pursuing consistency evaluations for its generic drugs to adapt to market changes driven by centralized volume-based procurement (CP) policies.

Recent Strategic Developments:

• Consistency Evaluation: Helpson's flagship product, Candesartan, passed its generic-drug-consistency-evaluation in August 2023. The Company continues to prioritize consistency evaluations for several key products.
• Comprehensive Healthcare & Protective Products: Continued exploration of the comprehensive healthcare market, including the launch of Noni enzyme in 2018, and wash-free sanitizers and various masks (including N95 Medical Protective masks in early 2023) in response to market needs. Freeze-dried bird's nest and Buddha's hand rose products are planned for launch.
• CDMO Services: Began serving as a Contract Manufacturing Organization (CMO) in April 2024, generating $33,227 in revenue in 2025. This project completed process verification in January 2025 and is undergoing NMPA registration.
• Product Portfolio Expansion: Acquired invention patents and formulas for dry eye syndrome, chronic obstructive pulmonary disease, psoriasis, psoriatic arthritis, riboflavin stomach floating tablet, gray nail disease, ansetropi simvastatin, Apremilast Vector, Captopril microcapsule, Ipragliflozin tablets, Topiroxostat Nanoemulsion, and Prinsepia Utilis Esterol Sublingual Tablets.

Geographic Footprint: All operations, manufacturing facilities, and customers are located exclusively within the People's Republic of China, specifically in Haikou, Hainan Province.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: -3.2%
• Operating Margin: -78.2%
• Net Margin: -76.9%

Investment in Growth:

• R&D Expenditure: $0.28 million (6.8% of revenue)
• Capital Expenditures: $0.06 million (Purchases of property, plant and equipment, net)
• Strategic Investments: $0.08 million (Advances for intangible assets)

Business Segment Analysis

CNS Cerebral & Cardio Vascular

Financial Performance:

• Revenue: $1.32 million (-2.2% YoY)
• Key Growth Drivers: Decrease mainly due to a decline in sales of Candesartan.

Product Portfolio:

• Major product lines and services within segment: Cerebroprotein Hydroloysate Injection, Gastrodin Injection, Propylgallate for Injection, Ozagrel Sodium for Injection, Alginic Sodium Diester Injection, Bumetanide for Injection, Candesartan.
• New product launches or major updates: Candesartan passed consistency evaluation in August 2023.

Market Dynamics:

• Competitive positioning within segment: Operates in a competitive market with off-patent branded generics.

Anti-Viral/ Infection & Respiratory

Financial Performance:

• Revenue: $2.48 million (-9.8% YoY)
• Key Growth Drivers: Decrease mainly due to a decline in sales of Cefaclor Dispersible Tablets, attributed to Helpson not passing the consistency evaluation of Roxithromycin and thus being unable to participate in Centralized Procurement (CP).

Product Portfolio:

• Major product lines and services within segment: Roxithromycin Dispersible Tablets, Cefaclor Dispersible Tablets, Cefalexin Capsules, Andrographolide, Clarithromycin Granules and Capsules, Naproxen Sodium and Pseudophedrine Hydrochloride Tablets.
• New product launches or major updates: N95 Medical Protective masks launched in early 2023.

Market Dynamics:

• Competitive positioning within segment: Impacted by CP policies and consistency evaluation requirements.

Digestive Diseases

Financial Performance:

• Revenue: $0.23 million (+15.0% YoY)
• Key Growth Drivers: Increase mainly due to higher sales of Omeprazole as a result of market fluctuations.

Product Portfolio:

• Major product lines and services within segment: Hepatocyte Growth-promoting Factor for Injection, Tiopronin, Compound Ammonium Glycyrrhetate S for Injection, Omeprazole.

Other

Financial Performance:

• Revenue: $0.07 million (-61.1% YoY)
• Key Growth Drivers: Decrease mainly due to a decline in sales of Vitamin B6 for Injection due to market volatility.
• OEM income: $33,227, accounting for 1% of total revenue in 2025, from Contract Manufacturing Organization (CMO) services.

Product Portfolio:

• Major product lines and services within segment: Vitamin B6 for Injection, Granisetron Hydrochloride Injection, Noni Enzyme, Sanitizer, Masks (KN95 Particulate Respirator, Disposable Medical Masks).

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: The Company has never paid or declared any cash dividends on its common stock and does not anticipate paying any in the foreseeable future.
• Future Capital Return Commitments: The Company does not intend to have any dividend distribution in the future.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $0.35 million
• Total Debt: $3.60 million (includes current portion of lines of credit, borrowings from related parties, and lease liabilities)
• Net Cash Position: -$3.25 million (Net Debt)
• Debt Maturity Profile:
  • RMB 5,000,000 (approximately $0.7 million) line of credit due June 20, 2026.
  • RMB 10,000,000 (approximately $1.4 million) revolving loan due September 20, 2026.
  • RMB 4,770,000 (approximately $0.74 million) loan from Chairperson Li due July 9, 2026.
  • RMB 1,000,000 (approximately $0.14 million) advance from Chunming Dong (interest-free until December 31, 2025, then 3.3% annual interest, payable within one year of loan agreement in June 2025).
  • RMB 1,750,000 (approximately $0.25 million) loan from Chairperson Li (interest-free if repaid by December 31, 2025, then 3.3% annual interest, payable within one year of loan agreement in June 2025).

Cash Flow Generation (for the year ended December 31, 2025):

• Operating Cash Flow: $0.15 million
• Free Cash Flow: $0.09 million
• Cash Conversion Metrics: Net trade accounts receivable increased by $0.01 million to $0.24 million. Total inventory decreased to $1.62 million from $2.27 million.

Operational Excellence

Production & Service Model: Helpson is engaged in the development, manufacture, and marketing of pharmaceutical products, including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. It also produces comprehensive healthcare and protective products. The Company employs an academic-driven promotion model, providing evidence-based medical support to medical institutions. It is actively exploring Contract Manufacturing Organization (CMO) services.

Supply Chain Architecture: The Company relies on numerous suppliers in the PRC and overseas for raw materials. It maintains at least three principal suppliers for each of its most critical raw materials.

Key Suppliers & Partners:

• Raw Material Suppliers: For the year ended December 31, 2025, the top three suppliers accounted for 26.6%, 26.3%, and 9.6% of raw material purchases, respectively.
• Technology Partners: Chengdu Bonier Medical Technology Development Co., Ltd., Tao Liu, Lihua Li, Li Yong, Zhao Xijun, Zhao Chunhai, Du Pingping, Yan Yang, Lijie Tang, Juan Zhang, Xiaoyun Chen, Xiaoyan Zhang for various patent and formula acquisitions.

Facility Network:

• Manufacturing: Two production facilities in Haikou, Hainan Province, PRC. One facility has a construction area of 663.94 square meters. The other factory has two buildings with production areas of 20,282.42 square meters and 6,593.20 square meters. All production lines (tablets, capsules, dry powder, liquid injectables, solid oral solution Cephalosporins, health care products, and masks) comply with the PRC’s Good Manufacturing Practices (GMP) standards and the New Drug Administration Law (effective December 1, 2019).
• Research & Development: R&D efforts are focused on promoting consistency evaluation of existing products and exploring comprehensive health product categories.
• Distribution: Warehousing and logistics infrastructure are managed through provincial and municipal pharmaceutical logistic companies.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Products are supplied directly to hospitals and OTC pharmacies through provincially and municipally licensed pharmaceutical logistic companies holding valid Drug Supply Licenses and GSP certifications, ensuring comprehensive coverage of primary healthcare markets.
• Digital Platforms: The Company is deploying digital marketing channels and collaborating with internet hospitals to enable compliant e-prescription transfers to partnered pharmacies, utilizing an S2B2C (Supplier-to-Business-to-Consumer) model.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Approximately 80% of the Company's end-customers are hospitals. The Company has established long-standing relationships with key hospital and clinic administrators and physicians through promotional efforts and seminars.
• Customer Concentration: For the year ended December 31, 2025, no single customer accounted for more than 10.0% of sales. Three customers accounted for 39.2%, 14.4%, and 9.2% of accounts receivable. The top five distributors collectively accounted for 23% of net revenues.

Geographic Revenue Distribution:

• PRC: 100% of total revenue. All customers are located in the PRC.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: China's pharmaceutical industry is highly policy-driven, influenced by generic drug consistency evaluations and centralized volume-based procurement (CP), which have led to significant price reductions. The market is characterized by a large number of small and medium-sized manufacturers, low industrial concentration, and intense competition over homogeneous products. Population aging and rising healthcare demand are key drivers, but medical insurance cost-control policies constrain growth. The Traditional Chinese Medicine (TCM) sector is experiencing revitalization and growth, with its industrial chain reaching RMB 1.05 trillion (approximately USD 146 billion) in 2024.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The Company faces intense competition from both local and overseas pharmaceutical enterprises manufacturing and selling substitute or similar products in the PRC. These competitors often possess greater capital, R&D resources, manufacturing and marketing capabilities, and experience. Increased competition from foreign pharmaceutical products, especially high-end products, is a result of lower import tariffs and foreign manufacturers establishing production facilities in the PRC following WTO admission.

Competitive Response Strategy: The Company's strategy includes promoting existing brands, accelerating consistency evaluations for main products, exploring the consumption healthcare market, expanding its distribution network (including digital marketing and internet hospitals), exploring CDMO services, and selectively acquiring complementary product lines, technologies, distribution networks, and companies.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company is highly susceptible to changes in PRC government policies, including generic drug consistency evaluation and centralized volume-based procurement (CP), which can significantly impact market landscape and drug pricing. Reimbursement policies under the National Medical Insurance Program (EDL, NIC) also affect product affordability and sales. Technology Disruption: The pharmaceutical industry is characterized by rapid technological changes and new product emergence, posing risks of existing products becoming obsolete or less competitive. Customer Concentration: Approximately 80% of end-customers are hospitals. The Company relies on a limited number of distributors, with the top five accounting for 23% of net revenues in 2025, creating dependency risks.

Operational & Execution Risks

Supply Chain Vulnerabilities: The Company relies on numerous suppliers for raw materials, with the top three suppliers accounting for 26.6%, 26.3%, and 9.6% of raw material purchases in 2025, respectively. Disruptions or unfavorable terms from these key suppliers could adversely affect operations. Geographic Concentration: All manufacturing and operations are concentrated in Hainan, China, making the Company vulnerable to regional natural disasters (e.g., typhoons), power shortages, and local policy changes. Capacity Constraints: While not a current issue, the Company anticipates a potential need for expansion and additional space as production increases.

Financial & Regulatory Risks

Market & Financial Risks: The Company has incurred recurring losses, has net current liabilities, and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern. It relies on advances from its CEO for working capital. Foreign Exchange: Substantially all revenue is in Renminbi, which is not freely convertible. PRC government controls on currency conversion and fluctuations in the Renminbi exchange rate can impact the Company's ability to fund activities outside China or make U.S. dollar payments. Credit & Liquidity: The Company faces liquidity challenges, with a working capital deficit of $5.1 million as of December 31, 2025. Its ability to raise additional funds is uncertain. Regulatory & Compliance Risks: The PRC legal system has inherent uncertainties, with evolving laws and regulations (e.g., Drug Administration Law, NMPA standards, CSRC filing requirements, cybersecurity, data privacy). Non-compliance or changes in interpretation could lead to fines, operational suspensions, or increased costs. Product liability claims are a risk, and product liability insurance is not available in the PRC.

Geopolitical & External Risks

Geographic Dependencies: The Company's exclusive operations in the PRC expose it to adverse changes in China's political and economic policies, government intervention, and legal system uncertainties. Trade Relations: China's WTO membership has intensified competition from imported and foreign-manufactured pharmaceutical products. Sanctions & Export Controls: The Holding Foreign Companies Accountable Act (HFCAA) and Accelerating Holding Foreign Companies Accountable Act (AHFCAA) pose risks related to PCAOB inspection of the Company's auditor, potentially leading to delisting from U.S. exchanges if inspection access is impeded.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: The Company focuses on the research and development of both first generic drugs and innovative drugs, as well as comprehensive health product categories. A key R&D effort is promoting the consistency evaluation of several major existing products. Innovation Pipeline: Helpson has recently acquired formulas and invention patents for a range of conditions, including dry eye syndrome, chronic obstructive pulmonary disease, psoriasis, psoriatic arthritis, gray nail disease, riboflavin stomach floating tablet, ansetropi simvastatin, Apremilast Vector, Captopril microcapsule, Ipragliflozin tablets, Topiroxostat Nanoemulsion, and Prinsepia Utilis Esterol Sublingual Tablets, with plans to launch these products upon registration completion.

Intellectual Property Portfolio:

• Patent Strategy: The Company relies on patent, trademark, and trade secret law. It holds 15 registered trademarks, including for eight of its 19 pharmaceutical products. It has acquired multiple invention patents related to medical formulas and therapeutic apparatuses, with expiration dates ranging from 2025 to 2029 and beyond for newer acquisitions.
• IP Litigation: The Company has not experienced any infringements of its trademarks or exclusive patent licenses to date and is not aware of any current infringements.

Technology Partnerships: The Company cooperates with research institutions and universities in the PRC for the research and development of certain new products, maintaining long-term collaborative relationships.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company is highly dependent on its principal management team, particularly Ms. Zhilin Li.

Board Composition: The Board of Directors includes three independent directors: Gene Michael Bennett, Yingwen Zhang, and Baowen Dong. Mr. Bennett serves as the Chairperson of the Audit Committee and is an "audit committee financial expert."

Human Capital Strategy

Workforce Composition:

• Total Employees: As of December 31, 2025, the Company had 221 employees, comprising 215 full-time and 6 temporary employees.
• Geographic Distribution: The workforce is primarily located in the PRC, where all operations are conducted.

Talent Management: Acquisition & Retention: The Company faces intense competition for qualified personnel, including scientific, marketing, and sales staff. It aims to provide competitive compensation packages, but acknowledges that many competitors have greater resources. Development Programs: The Company enhances employee training in production techniques and cost management principles to foster a culture of cost awareness.

Environmental & Social Impact

Environmental Commitments: Helpson complies with the Environmental Protection Law of China and applicable local regulations. The Company actively ensures the environmental sustainability of its operations and holds a waste disposal permit for its manufacturing facility, which is subject to periodic renewal (current permit expires February 2028).

Social Impact Initiatives: The Company states a passion for protecting human health and adherence to high ethical standards.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: The Company operates under the stringent regulatory framework of the NMPA in the PRC, including the Drug Administration Law (2019 revised version) and GMP standards. It is subject to consistency evaluations for generic drugs and centralized volume-based procurement (CP) policies. Products are also subject to the PRC's Medical Insurance System, including inclusion in the National Insurance Catalogue (NIC) and National Essential Drug List (EDL). International Compliance: As a U.S. publicly listed company, China Pharma Holdings, Inc. is subject to U.S. federal securities laws, including the Holding Foreign Companies Accountable Act (HFCAA) and Accelerating Holding Companies Accountable Act (AHFCAA), which relate to PCAOB inspection of auditors. It is also subject to CSRC filing requirements for future overseas securities offerings and the Foreign Corrupt Practices Act (FCPA). Data Privacy: The Company is subject to evolving PRC laws and regulations concerning cybersecurity, information security, privacy, and data protection, including the PRC Data Security Law, PRC Personal Information Protection Law, and various measures issued by the Cyberspace Administration of China (CAC) regarding cross-border data transfers, compliance audits, and incident reporting.

Legal Proceedings: The Company is not currently aware of any material legal proceedings or claims that would have a material adverse effect on its business, financial condition, or operating results.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company's PRC subsidiary is subject to an enterprise income tax rate of 25%.
• Geographic Tax Planning: Dividends payable by the Company to non-resident enterprise investors may be subject to a 10% PRC income tax. There is uncertainty regarding the classification of the Company as a "resident enterprise" in China, which could subject its worldwide income to a 25% PRC enterprise income tax. Gains on the sale of shares by non-PRC resident enterprise investors may also be subject to PRC withholding tax.
• Tax Reform Impact: The Company is assessing the impact of the U.S. One Big Beautiful Bill Act (OBBBA) enacted in July 2025, which includes significant provisions related to U.S. federal corporate income tax.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: The Company has limited insurance coverage, primarily property insurance for some buildings, vehicles, and equipment. It does not carry product liability insurance in the PRC, business interruption insurance, or directors' and officers' (D&O) insurance.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.